ECSP19031545A - Composiciones de células t con car anti-bcma - Google Patents

Composiciones de células t con car anti-bcma

Info

Publication number
ECSP19031545A
ECSP19031545A ECSENADI201931545A ECDI201931545A ECSP19031545A EC SP19031545 A ECSP19031545 A EC SP19031545A EC SENADI201931545 A ECSENADI201931545 A EC SENADI201931545A EC DI201931545 A ECDI201931545 A EC DI201931545A EC SP19031545 A ECSP19031545 A EC SP19031545A
Authority
EC
Ecuador
Prior art keywords
bcma car
cell compositions
cell
compositions
bcma
Prior art date
Application number
ECSENADI201931545A
Other languages
English (en)
Inventor
Robert Ross
Travis Quigley
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of ECSP19031545A publication Critical patent/ECSP19031545A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención provee composiciones de células T con CAR anti-BCMA mejoradas para terapia con células T adoptivas de mieloma múltiple recidivante/refractario.
ECSENADI201931545A 2016-11-04 2019-05-07 Composiciones de células t con car anti-bcma ECSP19031545A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662417840P 2016-11-04 2016-11-04
US201762514401P 2017-06-02 2017-06-02

Publications (1)

Publication Number Publication Date
ECSP19031545A true ECSP19031545A (es) 2019-08-30

Family

ID=62076928

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201931545A ECSP19031545A (es) 2016-11-04 2019-05-07 Composiciones de células t con car anti-bcma

Country Status (15)

Country Link
US (3) US12109234B2 (es)
EP (1) EP3534968A4 (es)
JP (2) JP7093346B2 (es)
KR (2) KR20240005168A (es)
CN (1) CN110022906A (es)
AU (2) AU2017355504C1 (es)
BR (1) BR112019009099A2 (es)
CA (1) CA3042424A1 (es)
CL (1) CL2019001224A1 (es)
CO (1) CO2019004630A2 (es)
EC (1) ECSP19031545A (es)
IL (1) IL266316B2 (es)
MA (1) MA46723A (es)
MX (1) MX2019005277A (es)
WO (1) WO2018085690A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2014152177A1 (en) 2013-03-15 2014-09-25 Anthrogenesis Corporation Modified t lymphocytes
RS60544B1 (sr) 2014-04-25 2020-08-31 Bluebird Bio Inc Poboljšani metodi za proizvodnju adoptivnih ćelijskih terapija
RU2747457C2 (ru) 2014-07-24 2021-05-05 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
PL3230321T3 (pl) 2014-12-12 2020-03-31 Bluebird Bio, Inc. Chimeryczne receptory antygenowe bcma
US12109234B2 (en) 2016-11-04 2024-10-08 2Seventy Bio, Inc. Anti-BCMA CAR T cell compositions
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
MX2021000283A (es) * 2018-07-11 2021-06-18 Celgene Corp Usos de los receptores del antigeno quimerico anti-bcma.
CN109134665B (zh) * 2018-08-24 2021-06-11 上海先博生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
WO2020051562A2 (en) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions and methods for improving base editing
EP3847254A4 (en) 2018-09-07 2022-08-10 Beam Therapeutics Inc. COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM
EA202190926A1 (ru) * 2018-10-01 2021-06-25 Эдисет Био, Инк. Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей
MA54079A (fr) 2018-11-01 2021-09-08 Juno Therapeutics Inc Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
AU2019372331A1 (en) * 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
KR20210111247A (ko) 2018-11-08 2021-09-10 주노 쎄러퓨티크스 인코퍼레이티드 치료 및 ｔ 세포 조절을 위한 방법 및 조합
ES3027934T3 (en) * 2018-11-16 2025-06-17 Rapa Therapeutics Llc Methods for treating cancer with manufactured t cells
US20220096548A1 (en) * 2019-01-07 2022-03-31 Hunan Siweikang Therapeutics Co. Ltd. Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
EP3733707A1 (en) * 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
US20210047423A1 (en) 2019-08-16 2021-02-18 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
CN110679588A (zh) * 2019-10-23 2020-01-14 厦门生命互联科技有限公司 一种嵌合抗原受体t细胞冻存介质及用途
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
EP4142723A2 (en) * 2020-04-28 2023-03-08 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
CN116685349A (zh) 2020-09-25 2023-09-01 比姆医疗股份有限公司 抗自相残杀的修饰的免疫细胞及其使用方法
AU2021393434A1 (en) * 2020-12-02 2023-06-22 Shanghai AbelZeta Ltd. Bcma-targeted chimeric antigen receptors
CN117529333A (zh) 2021-04-16 2024-02-06 细胞基因公司 对先前进行过干细胞移植的患者的t细胞疗法
KR20240112994A (ko) 2021-11-03 2024-07-19 셀진 코포레이션 골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
KR20250047766A (ko) 2022-08-05 2025-04-04 주노 쎄러퓨티크스 인코퍼레이티드 Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
EP4611798A1 (en) 2022-11-02 2025-09-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024123836A1 (en) 2022-12-06 2024-06-13 Dynamic Cell Therapies, Inc. Immune-activating complexes
EP4630446A1 (en) 2022-12-06 2025-10-15 Dynamic Cell Therapies, Inc. Engineered switches for immune cell activity and methods of use thereof
WO2024168192A1 (en) 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
EP4683948A1 (en) 2023-03-21 2026-01-28 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
CA3278900A1 (en) 2023-03-31 2024-10-03 AbelZeta Inc. BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA
CA3205511A1 (en) * 2023-04-19 2025-03-17 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
KR20240172697A (ko) 2023-05-30 2024-12-10 아주대학교산학협력단 Pd-l1을 표적으로 하는 키메라 항원 수용체 및 이를 발현하는 t 세포 치료제
WO2025141187A1 (en) 2023-12-29 2025-07-03 Fundación Para La Investigación Biomédica Del Hospital Universitario 12 De Octubre T cells expressing anti-bcma/anti-cd3 bispecific antibodies and uses thereof
TW202540428A (zh) 2024-01-26 2025-10-16 美商雷傑納榮製藥公司 使用漿細胞耗乏劑及／或ｂ細胞耗乏劑遏制宿主抗ａａｖ抗體反應且實現ａａｖ轉導及重複給藥的方法及組成物
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025255266A1 (en) 2024-06-05 2025-12-11 Dynamic Cell Therapies, Inc. Engineered polypeptides for immune cell activation

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE86967T1 (de) 1988-01-09 1993-04-15 Asta Medica Ag 1,2-bis(aminomethyl)cyclobutan-platin-komplexe.
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
DE4415263C1 (de) 1994-04-15 1995-11-30 Asta Medica Ag Cis-[trans-1,2-Cyclobutanbis(methylamin)-N,N']-[(2S)-lactato-O·1·, O·2·]-platin(II)-trihydrat (Lobaplatin-Trihydrat), seine Herstellung und arzneiliche Verwendung
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2247131A1 (en) 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
US20020177125A1 (en) 1997-03-04 2002-11-28 Kamb Carl Alexander Human rhinovirus assays, and compositions therefrom
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
DK1623017T3 (da) 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
EP1765988B1 (en) 2004-05-27 2017-09-20 The Trustees of The University of Pennsylvania Novel artificial antigen presenting cells and uses therefor
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
US7260418B2 (en) 2004-09-29 2007-08-21 California Institute Of Technology Multi-element phased array transmitter with LO phase shifting and integrated power amplifier
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
AU2006251621A1 (en) 2005-05-20 2006-11-30 Virxsys Corporation Transduction of primary cells
WO2007018318A1 (ja) 2005-08-10 2007-02-15 National University Corporation Kanazawa University 小脳星状細胞及び／又は籠細胞特異的な遺伝子発現方法
EP2094837B1 (en) 2006-12-14 2012-04-25 Medical Research Council Use of pi3k, m-tor and akt inhibitors to induce foxp3 expression and generate regulatory t cells
AU2008262487B2 (en) 2007-05-23 2013-10-31 Sangamo Therapeutics, Inc. Methods and compositions for increased transgene expression
ES2688721T3 (es) 2007-11-01 2018-11-06 Astellas Pharma Inc. Polipéptidos y ácidos nucleicos inmunosupresores
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
ES2961498T3 (es) 2008-08-26 2024-03-12 Hope City Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
ES2647351T3 (es) 2008-12-05 2017-12-21 Abraxis Bioscience, Llc Péptidos de unión a SPARC y usos de los mismos
HRP20161194T1 (hr) 2009-03-10 2016-11-04 Biogen Ma Inc. Anti-bcma protutijela
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
HUE044461T2 (hu) 2009-11-03 2019-10-28 Hope City Csonkolt epidermális növekedési faktor receptor (EGFRT) transzdukált T-sejt szelekcióhoz
US8999398B2 (en) 2009-11-06 2015-04-07 Transtarget Inc. Polyclonal bispecific antibody compositions and method of use
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
EP2614143B1 (en) 2010-09-08 2018-11-07 Baylor College Of Medicine Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2824997C (en) 2011-01-18 2023-01-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
US20160002601A1 (en) 2011-03-03 2016-01-07 Stempeutics Research Pvt. Ltd. Methods of upscaling mesenchymal stromal cell production, compositions and kit thereof
AU2012230780B2 (en) 2011-03-23 2016-10-27 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
CN103502439B (zh) 2011-04-13 2016-10-12 因缪尼卡姆股份公司 用于抗原特异性t细胞增殖的方法
FI3415531T3 (fi) 2011-05-27 2023-09-07 Glaxo Group Ltd Bcma:aa (cd269/tnfrsf17) sitovia proteiineja
JP6143231B2 (ja) 2011-06-10 2017-06-07 ブルーバード バイオ， インコーポレイテッド 副腎脳白質ジストロフィおよび副腎脊髄神経障害のための遺伝子療法ベクター
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
AU2013222267A1 (en) 2012-02-22 2014-07-31 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
KR20240136359A (ko) 2012-04-11 2024-09-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
AU2013204923A1 (en) 2012-06-21 2014-01-16 Anthrogenesis Corporation Modified t lymphocytes having improved specificity
EP3584256A1 (en) 2012-07-13 2019-12-25 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced t cells for administration
PT3824905T (pt) 2012-08-20 2025-03-21 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapêutica celular
PT2893004T (pt) 2012-09-04 2019-01-21 Cellectis Recetor de antígeno quimérico de cadeia múltipla e utilizações do mesmo
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
AR092745A1 (es) 2012-10-01 2015-04-29 Univ Pennsylvania Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
US9597357B2 (en) 2012-10-10 2017-03-21 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
EP3623380B1 (en) 2013-03-15 2025-10-22 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3102609B1 (en) 2014-02-04 2024-08-28 The United States of America, as Represented by The Secretary, Department of Health and Human Services Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
CA2937750A1 (en) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
JP6698546B2 (ja) 2014-04-14 2020-05-27 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
LT3689899T (lt) 2014-04-25 2021-12-10 2Seventy Bio, Inc. Mnd promotorių chimerinių antigenų receptoriai
RS60544B1 (sr) 2014-04-25 2020-08-31 Bluebird Bio Inc Poboljšani metodi za proizvodnju adoptivnih ćelijskih terapija
WO2015164739A1 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
MX380612B (es) 2014-06-06 2025-03-12 2Seventy Bio Inc Composiciones de celulas t mejoradas.
JP7054622B2 (ja) * 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
RU2747457C2 (ru) 2014-07-24 2021-05-05 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
PL3230321T3 (pl) 2014-12-12 2020-03-31 Bluebird Bio, Inc. Chimeryczne receptory antygenowe bcma
WO2016154628A1 (en) 2015-03-26 2016-09-29 Xiuli Wang Bi-specific targeted chimeric antigen receptor t cells
WO2016164408A1 (en) 2015-04-06 2016-10-13 The General Hospital Corporation Anti-cspg4 reagents and methods of treating cancer
CN108137669B (zh) 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
EP3362470B1 (en) 2015-10-13 2021-09-22 City of Hope Chimeric antigen receptors containing a chlorotoxin domain
IL305306B2 (en) 2015-10-20 2025-08-01 Us Health Methods of preparing t cells for t cell therapy
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
US12109234B2 (en) 2016-11-04 2024-10-08 2Seventy Bio, Inc. Anti-BCMA CAR T cell compositions
EP3645568B1 (en) 2017-06-30 2022-08-17 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-b-cell maturation antigen chimeric antigen receptors with human domains
JP2020528885A (ja) 2017-07-19 2020-10-01 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
AU2020254699A1 (en) 2019-04-05 2021-12-02 2Seventy Bio, Inc. Manufacturing anti-BCMA CAR T cells
CN112980886B (zh) 2019-12-02 2022-02-22 河北森朗生物科技有限公司 一种能高效制备且应用安全的嵌合抗原受体t细胞及其制备方法与应用

Also Published As

Publication number Publication date
MX2019005277A (es) 2019-09-27
IL266316B2 (en) 2025-07-01
AU2024203372A1 (en) 2024-07-11
WO2018085690A1 (en) 2018-05-11
AU2017355504B2 (en) 2024-02-22
JP2022113883A (ja) 2022-08-04
CN110022906A (zh) 2019-07-16
EP3534968A4 (en) 2020-07-01
AU2017355504A1 (en) 2019-05-23
IL266316B1 (en) 2025-03-01
CL2019001224A1 (es) 2019-10-18
KR20190082241A (ko) 2019-07-09
BR112019009099A2 (pt) 2019-07-16
JP7385709B2 (ja) 2023-11-22
JP7093346B2 (ja) 2022-06-29
US20250064722A1 (en) 2025-02-27
CA3042424A1 (en) 2018-05-11
MA46723A (fr) 2019-09-11
KR20240005168A (ko) 2024-01-11
IL266316A (en) 2019-06-30
US12109234B2 (en) 2024-10-08
NZ753088A (en) 2025-05-30
JP2020502048A (ja) 2020-01-23
AU2017355504C1 (en) 2024-06-20
US20250064723A1 (en) 2025-02-27
US20200261501A1 (en) 2020-08-20
CO2019004630A2 (es) 2019-05-21
EP3534968A1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
ECSP19031545A (es) Composiciones de células t con car anti-bcma
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2018001556A1 (es) Receptores de antígenos quiméricos (car) de bcma. (solicitud divisional 201701515)
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
MX2017001079A (es) Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
PH12015502048A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
CL2016001871A1 (es) Anticuerpos humanos para pd-1
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
UY37018A (es) Inhibidores bicíclicos de pad4
MX2018003353A (es) Terapias con celulas cart con una eficacia mejorada.
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
PH12017500660A1 (en) Novel compositions, uses and methods for making them
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
PH12017501864A1 (en) Compositions and methods for treating autism
MX2017011116A (es) Composiciones novedosas, usos y metodos para hacerlas.